PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Clear cell renal cell carcinoma (ccRCC) is a significant health concern with common VHL and SETD2 mutations.
• Identifying targeted therapies for specific ccRCC mutations is crucial for improving patient outcomes.
• The PI3K/AKT pathway plays a critical role in ccRCC pathogenesis.

Purpose of the Study:

• To discover novel compounds with high selectivity for ccRCC harboring VHL and/or SETD2 mutations.
• To investigate the therapeutic potential of identified compounds in preclinical models.
• To analyze the clinical impact and gene interactions associated with VHL, SETD2, PTEN, and CDKN2A mutations in ccRCC.

Main Methods:

• Utilized the Genomics of Drug Sensitivity in Cancer (GDSC) database to screen for selective compounds.
• Employed The Cancer Genome Atlas (TCGA) database for clinical impact and gene interaction analysis.
• Conducted in vitro and in vivo studies to validate the efficacy and selectivity of the lead compound.

Main Results:

• Identified TGX221, a selective PI3Kβ inhibitor, as a potent inhibitor of ccRCC with combined VHL and SETD2 mutations.
• TGX221 demonstrated selectivity against cancer cells with additional PTEN and CDKN2A mutations, which are linked to poorer prognosis.
• The compound selectively inhibited downstream signaling of VHL, SETD2, and PTEN, and suppressed ccRCC cell motility and tumorigenesis.

Conclusions:

• TGX221 is a novel, highly selective inhibitor for ccRCC with VHL and SETD2 mutations.
• TGX221 also exhibits activity against ccRCC with PTEN and CDKN2A mutations, suggesting broader therapeutic potential.
• Further investigation is warranted to elucidate the precise mechanisms linking these genes to PI3Kβ activity in ccRCC.